Quarterly report pursuant to Section 13 or 15(d)

Segment Information

v3.21.1
Segment Information
6 Months Ended
Apr. 30, 2021
Segment Reporting [Abstract]  
Segment Information

11. SEGMENT INFORMATION

 

We follow the accounting guidance of ASC 280 “Segment Reporting” (“ASC 280”). Reportable operating segments are determined based on the management approach. The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker organizes the segments within an enterprise for making operating decisions and assessing performance. While our results of operations are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in five reportable segments, each with different operating and potential revenue generating characteristics: (i) CAR-T Therapeutics, (ii) Cancer Vaccines, (iii) Anti-Viral Therapeutics, (iv) Cancer Diagnostics and (v) Patent Licensing activities. The following represents selected financial information for our segments for the three and six months ended April 30, 2021 and 2020 and as of April 30, 2021 and October 31, 2020:

 

    For the Three Months Ended
April 30,
    For the Six Months Ended
April 30,
 
    2021     2020     2021     2020  
Net Income/(Loss):                                
CAR-T Therapeutics   $ (1,445,758 )   $ (495,030 )   $ (2,406,494 )   $ (1,125,363 )
Cancer Vaccines     (662,367 )     (170,271 )     (1,568,703 )     (365,867 )
Anti-Viral Therapeutics     (309,755 )     (309,504 )     (790,561 )     (309,504 )
Cancer Diagnostics     (13,409 )     (1,679,027 )     (22,371 )     (3,469,673 )
Patent Licensing     (5,600 )     (4,158 )     118,863       (4,158 ))
Total   $ (2,436,889)     $ (2,657,990 )   $ (4,669,266 )   $ (5,274,565 )
                                 
Total operating costs and expenses   $ 2,437,282     $ 2,670,137     $ 5,182,913     $ 5,300,006  
Less non-cash share-based compensation     (1,051,272 )     (1,110,086 ))     (2,037,371 )     (2,131,420 )
Operating costs and expenses
excluding non-cash share-based
compensation
  $ 1,386,010     $ 1,560,051     $ 3,145,542     $ 3,168,586  
Operating costs and expenses excluding
non-cash share based compensation:
                               
CAR-T Therapeutics   $ 934,714     $ 223,822     $ 1,492,394     $ 570,163  
Cancer Vaccines     298,537       67,059       836,525       165,329  
Anti-Viral Therapeutics     138,175       221,018       408,431       221,018  
Cancer Diagnostics     10,291       1,044,889       16,723       2,208,813  
Patent Licensing     4,293       3,263       391,469       3,263  
Total   $ 1,386,010     $ 1,560,051       3,145,542     $ 3,168,586  

 

    April 30,
2021
    October 31,
2020
 
Total assets:                
CAR-T Therapeutics   $ 25,906,018     $ 2,988,124  
Cancer Vaccines     8,265,734       946,923  
Anti-Viral Therapeutics     3,825,876       2,464,361  
Cancer Diagnostics     332,450       2,869,529  
Patent Licensing     167,444       184,027  
Total   $ 38,497,522     $ 9,452,964  

 

Operating costs and expenses excluding non-cash share-based compensation expense is the measurement the chief operating decision-maker uses in managing the enterprise.